Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

AP26113 - Solving the Treatment Resistance Riddle, www.curetoday.com article, Dec. 8, 2013

Andy Bonnett has been dealing with drug-resistant lung cancer since 2008, but has benefited from clinical trials studying new therapies.

Bonnett has had to deal with further shifts in his cancer makeup and treatment. Last summer, his tumors began showing signs of resistance to Xalkori. He started to feel a return of the pain that marked his original disease. After returning from a kayaking trip for people with cancer, Bonnett underwent new scans, which revealed multiple lesions.

He was eligible, however, for a second clinical trial, one with a new agent, still unnamed, called AP26113, which also targets ALK in a different way. AP26113 seems to be able to make it through the blood-brain barrier, and today, Bonnett’s brain metastases are inactive.

Positive AP26113 progress:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94559928